Valuation method | Value, $ | Upside, % |
---|---|---|
Artificial intelligence (AI) | 168.16 | -9 |
Intrinsic value (DCF) | 12.32 | -93 |
Graham-Dodd Method | n/a | |
Graham Formula | 71.48 | -61 |
Becton, Dickinson and Company (BDX) is a global leader in medical technology, specializing in the development, manufacturing, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Serving healthcare institutions, physicians, researchers, and pharmaceutical companies, BDX operates through three key segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment focuses on infusion therapy, medication management, and diabetes care, while BD Life Sciences provides advanced diagnostic solutions, including microbiology and single-cell analysis. BD Interventional offers surgical and peripheral intervention products. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BDX plays a critical role in advancing healthcare innovation, with a strong emphasis on infection prevention, precision diagnostics, and surgical solutions. With a market cap exceeding $49 billion, BDX is a key player in the Medical Instruments & Supplies sector, benefiting from long-term healthcare demand and technological advancements.
Becton, Dickinson and Company (BDX) presents a stable investment opportunity within the healthcare sector, supported by its diversified product portfolio and strong market position. The company’s low beta (0.34) suggests resilience to market volatility, making it attractive for risk-averse investors. BDX generates steady revenue ($20.2B in FY2024) and maintains a solid dividend yield (~3.98 per share). However, its high total debt ($20.1B) and moderate net income ($1.7B) could pose financial constraints. The company’s focus on innovation in diagnostics and surgical solutions provides growth potential, but competition and regulatory pressures remain key risks. Investors should weigh BDX’s defensive healthcare positioning against its leverage and margin pressures.
BDX holds a competitive advantage through its diversified product offerings and strong brand recognition in medical technology. Its BD Medical segment dominates infusion therapy and diabetes care, while BD Life Sciences excels in diagnostic solutions, particularly in microbiology and cell analysis. The company’s scale and global distribution network provide cost efficiencies and market penetration. However, BDX faces intense competition from larger medtech firms like Medtronic and Abbott, which have broader portfolios and stronger R&D budgets. BDX’s BD Interventional segment competes with specialized players in surgical and urology products. While BDX benefits from recurring revenue via consumables (e.g., syringes, diagnostic reagents), its growth depends on innovation cycles and regulatory approvals. Pricing pressure in commoditized segments (e.g., basic syringes) and supply chain risks could erode margins. Overall, BDX’s competitive positioning is solid but requires sustained investment to maintain leadership in high-growth areas like molecular diagnostics and surgical robotics.